Federal funding cuts leave drug-checking groups scrambling for replacements
When federal money disappeared, North Carolina harm reduction workers were left to fill a gap that sits directly between street drugs and the next overdose death. For organizations serving people who use drugs, test strips are not an abstraction or a policy talking point. They are one of the few low-cost tools that can warn someone that a baggie contains fentanyl, xylazine, medetomidine, or another contaminant that can turn a routine use into respiratory arrest.
In Greenville, Diannee Carden Glenn had relied for much of the past decade on Substance Abuse and Mental Health Services Administration funding to buy test strips for ekiM for Change, the volunteer-run group she directs. In April, that federal support was cut off after the agency sent a “Dear Colleague” letter saying organizations could no longer use its money to buy strips for fentanyl, xylazine, medetomidine, or related substances. The federal allocation had been a little more than $15,000 a year. For a small operation working in eastern North Carolina, that sum covered a practical public health function that now has to be financed from retirement income, Social Security, and donations.
The policy shift lands at a dangerous moment. Fentanyl is already ubiquitous, and the drug supply is no longer defined by one contaminant alone. Outreach workers are encountering methamphetamine, carfentanil, medetomidine, nitazenes, and other ultrapotent compounds layered into materials sold on the street. In that setting, a person may believe they are using one drug and instead be exposed to a pharmacologic stack that increases the odds of unpredictable sedation, toxicity, or overdose. The test strip is a simple device, but the bedside consequence is immediate: more information before consumption can mean a narrower path to a fatal exposure.
Harm reduction advocates argue that these strips do exactly what public health should want them to do. They give people a chance to make a different decision, use less, avoid using alone, carry naloxone, or discard a sample they had planned to take. Research has linked strip use with other protective behaviors, including carrying overdose reversal medication and changing use practices when dangerous contaminants are detected. In a drug supply that changes rapidly, that kind of warning is often the only chance to interrupt an overdose cascade before it starts.
North Carolina’s testing network is broader than a single strip
The loss of federal support has not stopped testing in North Carolina, but it has made the work more expensive and harder to sustain. Carden Glenn said ekiM for Change typically hands out strips for fentanyl, xylazine, and medetomidine. Each strip can cost $1 or more, depending on the type, and handing out several hundred each week quickly becomes a budget problem for a small nonprofit. What once came through a federal channel now has to be replaced one purchase, one fundraiser, one donation at a time.
In Durham, another model is at work. Each Friday afternoon, workers with the North Carolina Harm Reduction Coalition arrive at Elizabeth Street United Methodist Church with a Fourier transform infrared spectroscopy machine, a compact device that can examine drug samples more thoroughly than a strip. The machine does not just answer yes or no on a single adulterant; it reveals a broader chemical profile and can identify a mixture that might otherwise remain hidden. Staff still keep strips on hand because the machine can miss traces of medetomidine in cocaine, showing why no single tool is enough when the supply is this unstable.
Jennifer Carroll, an associate professor of anthropology at North Carolina State University, works with the coalition to evaluate the results. Her description of the process sounds almost like epidemiology in real time: every sample is a mystery, and every answer can change what happens next. People who come to the site include both regular and occasional users, as well as friends, family members, or advocates carrying a sample on someone else’s behalf. The value is not just chemical identification. It is the restoration of agency in a setting where drug users are often stripped of it by uncertainty.
“We see quinine, lidocaine, tetracaine,” Carroll said. “We see tranquilizers like xylazine and medetomidine. We occasionally see gabapentin show up, but it’s not common. We occasionally see heroin.”
The list reads like a catalog of volatility. Some compounds are added to stretch product, some to alter its effects, and some appear in ways that remain difficult to explain from the outside. Either way, the result is the same: people consume a substance that no longer behaves like the drug they expected.
Street supply complexity is now the central threat
At the University of North Carolina-Chapel Hill’s Street Drug Analysis Lab, known as Nab’s Lab, the work goes even further. The lab has detected about 500 unique substances in the drug supply since its launch in 2022. Among the findings are levamisole, a medication used to treat worm infestation in animals, and BTMPS, an industrial chemical used to protect plastics from ultraviolet exposure. Those results capture how far the contamination problem has drifted from classic opioid overdose alone. The danger now includes unexpected pharmacology, impurities from industrial sources, and combinations no user can reasonably anticipate on sight.
Pearson Ripley of the Steady Collective in Asheville said keeping pace with adulterants is the hardest part of the work. Fentanyl was the initial shock to the system. The new problem is the speed and complexity of what is now circulating. Graphs of sample composition show a steady rise in the number of substances detected each year, a pattern that matches what frontline workers see in the field: more unknowns, more mixtures, more occasions when a strip or machine can change a decision before use.
Rural communities have built some of the most inventive responses. Nabarun Dasgupta, who directs Nab’s Lab, described some of these local programs as “engines of ingenuity.” Holler Harm Reduction, for example, brings drug checking to people’s homes and conducts driveway testing in western North Carolina. That kind of outreach reduces barriers in places where transportation, stigma, and distance can block access to services long before any public health recommendation reaches the people most at risk.
The same logic drives the Good Mind Initiative, which serves Indigenous communities across North and South Carolina. Its monthly gatherings at the United Katehnuaka Longhouse can bring together as many as 300 people for food, fellowship, first aid kits, naloxone, condoms, and other supplies. Kaya Littleturtle, the program manager, described culture, language, songs, and dances as integral to healing and harm reduction. Test strips fit into that framework as a practical tool, but the loss of funding now forces the group to rely on fundraising events and local effort to keep the service alive.
The federal cuts have not eliminated drug checking. They have simply shifted the burden onto small groups already operating close to the edge. In a supply increasingly defined by fentanyl, xylazine, medetomidine, nitazenes, and other adulterants, that shift leaves fewer people with any warning at all before exposure.